OBJECTIVE: Hepatitis C virus (HCV) infection is associated with decreased quality of life (QOL) and neurocognitive dysfunction in adults, but little is known about its impact on children and their caregivers. PATIENTS AND METHODS: We studied the QOL, behavioral, emotional, and cognitive functioning of 114 treatment-naïve children with HCV enrolled in aplacebo-controlled, randomized, multisite clinical trial evaluating peginterferon alpha-2a alone or with ribavirin. Baseline assessment included measures of children's QOL, cognitive functioning, behavioral adaptation, and depression. Caregivers' QOL also was assessed. RESULTS: Relative to published normative data, caregivers were more likely to believe that their children's health was poor and would likely worsen (t = 3.93; P < 0.0001), and reported higher concern about their children's health status (t = 6.63; P < 0.0001) and that this concern limited family activities (t = 2.45; P < 0.01); they also viewed their children as having more internalizing behavioral problems (t = 1.98; P < 0.05). Only 2 (2%) children had a score in the clinically depressed range. Children withHCV had worse cognitive functioning than the normative sample but significantly better functioning than children with attention-deficit/hyperactivity disorder. Caregivers' QOL scores did not differ significantly from the normative sample, but infected mothers had lower QOL than noninfected caregivers. Caregivers were highly distressed about their children's medical circumstances. CONCLUSIONS: Although HCV infection, in its early stages, does not lead to global impairment in QOL, cognitive, behavioral, or emotional functioning in children, it is associated with higher caregiver stress and strain on the family system, and it may be associated with some cognitive changes in children.
RCT Entities:
OBJECTIVE:Hepatitis C virus (HCV) infection is associated with decreased quality of life (QOL) and neurocognitive dysfunction in adults, but little is known about its impact on children and their caregivers. PATIENTS AND METHODS: We studied the QOL, behavioral, emotional, and cognitive functioning of 114 treatment-naïve children with HCV enrolled in a placebo-controlled, randomized, multisite clinical trial evaluating peginterferon alpha-2a alone or with ribavirin. Baseline assessment included measures of children's QOL, cognitive functioning, behavioral adaptation, and depression. Caregivers' QOL also was assessed. RESULTS: Relative to published normative data, caregivers were more likely to believe that their children's health was poor and would likely worsen (t = 3.93; P < 0.0001), and reported higher concern about their children's health status (t = 6.63; P < 0.0001) and that this concern limited family activities (t = 2.45; P < 0.01); they also viewed their children as having more internalizing behavioral problems (t = 1.98; P < 0.05). Only 2 (2%) children had a score in the clinically depressed range. Children with HCV had worse cognitive functioning than the normative sample but significantly better functioning than children with attention-deficit/hyperactivity disorder. Caregivers' QOL scores did not differ significantly from the normative sample, but infected mothers had lower QOL than noninfected caregivers. Caregivers were highly distressed about their children's medical circumstances. CONCLUSIONS: Although HCV infection, in its early stages, does not lead to global impairment in QOL, cognitive, behavioral, or emotional functioning in children, it is associated with higher caregiver stress and strain on the family system, and it may be associated with some cognitive changes in children.
Authors: J G McHutchison; J E Ware; M S Bayliss; S Pianko; J K Albrecht; S Cort; I Yang; M P Neary Journal: J Hepatol Date: 2001-01 Impact factor: 25.083
Authors: Daniel M Forton; Howard C Thomas; Christine A Murphy; Joanna M Allsop; Graham R Foster; Janice Main; Keith A Wesnes; Simon D Taylor-Robinson Journal: Hepatology Date: 2002-02 Impact factor: 17.425
Authors: Karen F Murray; Laura S Finn; Shari L Taylor; Kristy D Seidel; Anne M Larson Journal: J Pediatr Gastroenterol Nutr Date: 2005-11 Impact factor: 2.839
Authors: Parvathi Mohan; Camilla Colvin; Chevelle Glymph; Roma R Chandra; David E Kleiner; Kantilal M Patel; Naomi L C Luban; Harvey J Alter Journal: J Pediatr Date: 2007-02 Impact factor: 4.406
Authors: Kathleen B Schwarz; Regino P Gonzalez-Peralta; Karen F Murray; Jean P Molleston; Barbara A Haber; Maureen M Jonas; Philip Rosenthal; Parvathi Mohan; William F Balistreri; Michael R Narkewicz; Lesley Smith; Steven J Lobritto; Stephen Rossi; Alexandra Valsamakis; Zachary Goodman; Patricia R Robuck; Bruce A Barton Journal: Gastroenterology Date: 2010-10-28 Impact factor: 22.682
Authors: Lisa G Sorensen; Katie Neighbors; Song Zhang; Christine A Limbers; James W Varni; Vicky L Ng; Robert H Squires; Estella M Alonso Journal: J Pediatr Gastroenterol Nutr Date: 2015-01 Impact factor: 2.839
Authors: James R Rodrigue; William Balistreri; Barbara Haber; Maureen M Jonas; Parvathi Mohan; Jean P Molleston; Karen F Murray; Michael R Narkewicz; Philip Rosenthal; Lesley J Smith; Steven J Lobritto; Kathleen B Schwarz; Patricia R Robuck; Bruce Barton; Regino P González-Peralta Journal: Hepatology Date: 2011-05 Impact factor: 17.425
Authors: Sarah Jane Schwarzenberg; Simon C Ling; Yona Keich Cloonan; Hsing-Hua S Lin; Donna M Evon; Karen F Murray; Norberto Rodriguez-Baez; Philip Rosenthal; Jeffrey Teckman; Kathleen B Schwarz Journal: J Pediatr Gastroenterol Nutr Date: 2017-05 Impact factor: 2.839